Michael J. Overman, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Interim Results of the CheckMate 142 Trial
2016 ASCO Annual Meeting
Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).
Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).
Eduardo L. Cazap, MD, PhD, of the Latinamerican & Caribbean Society of Medical Oncology, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.
Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cell as consolidation therapy for high-risk neuroblastoma (Abstract LBA3).
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).
James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).
